Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BridgeBio Oncology Therapeutics Inc. (BBOT)
USD8.39
-0.43 (-4.87%)
US NASDAQ Healthcare Biotechnology
Address
256 E. Grand Avenue 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Eli Wallace
Website
bbotx.com
IPO
2025-08-12
CIK 1869105 ISIN US1079241022
Also trades on
NASDAQ Global Market · BBOT (USD)
NASDAQ Global Market · HLXB (USD)
Description
BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| MoonLake Immunotherapeutics | MLTX | 2025-06-20 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD8.39
-0.43 (-4.87%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
467.9K
Beta
0.29
Float Shares
453.0K
Free Float %
56.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.47% | +4.91% | +6.66% | -10.57% | -27.13% | -28.35% | -16.56% | -11.97% | -11.97% | -11.97% | -11.97% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
8.39
Low
18.00
+114.5%
Consensus
22.00
+162.2%
Median
23.00
+174.1%
High
24.00
+186.0%
DCF (Unlevered)
11.88
+41.6%
DCF (Levered)
11.91
+41.9%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 3 | 0 |
| Buy | 7 | +1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
23.00
+174.1%
|
| Last Quarter | 1 |
23.00
+174.1%
|
| Last Year | 9 |
22.67
+170.2%
|
| All Time | 9 |
22.67
+170.2%
|
Quality scores
Altman Z-Score
7.47
Safe zone
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-1,034.8% Q1'26: -2,541,494.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: -150.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+87.2% Q1'26: +240.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 EPS Ana. |
Dec 2027 8 Rev. Ana. 6 EPS Ana. |
Dec 2028 7 EPS Ana. |
Dec 2029 3 Rev. Ana. 2 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
|
—
— – —
|
29.05M
29.05M – 29.05M
|
—
— – —
-100.0% YoY
|
25.94M
25.94M – 25.94M
|
107.65M
107.65M – 107.65M
+315.0% YoY
|
| EBITDA |
-80.66M
|
-145.21M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-80.86M
|
-145.82M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-74.28M
est: -4.47B (+98.3%)
|
-134.04M
est: -100.02M (-34.0%)
|
-69.64M
-76.62M – -62.66M
+30.4% YoY
|
-66.68M
-71.47M – -61.89M
+4.2% YoY
|
-65.07M
-83.52M – -46.63M
+2.4% YoY
|
-61.85M
-61.85M – -61.85M
+4.9% YoY
|
-45.91M
-45.91M – -45.91M
+25.8% YoY
|
| SGA |
7.76M
|
24.62M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
0.46
est: -268.56 (+100.2%)
|
-4.30
est: -3.22 (-33.7%)
|
-2.24
-2.46 – -2.01
+30.3% YoY
|
-2.14
-2.29 – -1.99
+4.5% YoY
|
-2.10
-2.68 – -1.50
+1.8% YoY
|
-1.99
-1.99 – -1.99
+5.5% YoY
|
-1.47
-1.47 – -1.47
+25.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-26 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-22 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-21 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-20 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-19 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-18 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-15 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-14 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-13 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-12 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 1/5 | 1/5 | 4/5 | 1/5 | 4/5 |
| 2026-05-05 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-04 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-05-01 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
67
Total invested
513.83M
Insider transactions (90d)
4
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Chen | 7.42M | 31.70% | — | 7.42M | — | 7.42M | IN | States | 2024-02-20 | ↗ |
| 2 | Holdings II LLC | 5.02M | 21.40% | — | 5.02M | — | 5.02M | OO | Islands | 2024-02-20 | ↗ |
| 3 | Private Healthcare Fund III, LP | 1.43M | 7.50% | — | 1.43M | — | 1.43M | PN | Delaware | 2024-02-20 | ↗ |
| 4 | Private Healthcare GP III, LLC | 1.43M | 7.50% | — | 1.43M | — | 1.43M | OO | Delaware | 2024-02-20 | ↗ |
| 5 | Adage Capital Management, L.P. | 1.40M | 7.40% | — | 1.40M | — | — | IA, PN | Delaware | 2024-02-23 | ↗ |
| 6 | Adage Capital Partners GP, L.L.C. | 1.40M | 7.40% | — | 1.40M | — | — | OO | Delaware | 2024-02-23 | ↗ |
| 7 | Adage Capital Partners, L.P. | 1.40M | 7.40% | — | 1.40M | — | — | PN | Delaware | 2024-02-23 | ↗ |
| 8 | Phillip Gross | 1.40M | 7.40% | — | 1.40M | — | — | IN | United States | 2024-02-23 | ↗ |
| 9 | Robert Atchinson | 1.40M | 7.40% | — | 1.40M | — | — | IN | United States | 2024-02-23 | ↗ |
| 10 | 52-0556948 | 1.13M | 6.00% | 1.13M | — | 1.13M | — | IA | Maryland | 2024-11-14 | ↗ |
| 11 | Israel A. Englander | 1.10M | 5.80% | — | 1.10M | — | 1.10M | IN | Delaware | 2024-02-15 | ↗ |
| 12 | Millennium Group Management LLC | 1.10M | 5.80% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-02-15 | ↗ |
| 13 | Millennium Management LLC | 1.10M | 5.80% | — | 1.10M | — | 1.10M | OO | Delaware | 2024-02-15 | ↗ |
| 14 | Integrated Core Strategies (US) LLC | 950.0K | 5.00% | — | 950.0K | — | 950.0K | OO | Delaware | 2024-02-15 | ↗ |
| 15 | Caisse de dépôt et placement du Québec | 52.6K | 5.26% | 1.50M | — | 1.50M | — | OO | Delaware | 2024-11-08 | ↗ |
| 16 | 2. | 10.00 | 0.00% | — | 955.00 | — | — | HC, PN | Delaware | 2024-02-23 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
67
+14 vs prev Q
New positions
23
Closed positions
9
Increased
43
Reduced
11
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CORMORANT ASSET MANAGEMENT, LP | 17.88M +— (+0.0%) | 223.84M +16.8M (+8.1%) | 76.05% +0.000 pp | 10.35% -3.935 pp | USD11.58 +8.1% | 2 qtrs — |
| 2 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4.89M +— (+0.0%) | 61.17M +4.6M (+8.1%) | 20.78% +0.000 pp | 0.78% -0.083 pp | USD11.58 +8.1% | 2 qtrs — |
| 3 | OMEGA FUND MANAGEMENT, LLC | 3.29M +— (+0.0%) | 41.19M +3.1M (+8.1%) | 13.99% +0.000 pp | 14.37% -2.757 pp | USD11.58 +8.1% | 2 qtrs — |
| 4 | WELLINGTON MANAGEMENT GROUP LLP | 2.91M -54.3K (-1.8%) | 36.40M +2.1M (+6.1%) | 12.37% -0.231 pp | 0.01% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 5 | ECOR1 CAPITAL, LLC | 2.82M +— (+0.0%) | 35.35M +2.7M (+8.1%) | 12.01% +0.000 pp | 1.60% +0.035 pp | USD11.58 +8.1% | 2 qtrs — |
| 6 | ALPHABET INC. | 2.82M +— (+0.0%) | 35.35M +2.7M (+8.1%) | 12.01% +0.000 pp | 1.37% +0.013 pp | USD11.58 +8.1% | 2 qtrs — |
| 7 | ENAVATE SCIENCES GP, LLC | 2.63M +— (+0.0%) | 32.89M +2.5M (+8.1%) | 11.17% +0.000 pp | 6.49% -2.798 pp | USD11.58 +8.1% | 2 qtrs — |
| 8 | CITADEL ADVISORS LLC | 2.53M -7.8K (-0.3%) | 31.68M +2.3M (+7.8%) | 10.76% -0.033 pp | 0.00% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 9 | CATALIO CAPITAL MANAGEMENT, LP | 410.7K +410.7K (+100.0%) | 31.41M +31.4M (+100.0%) | 1.75% +1.747 pp | 5.55% +5.552 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 10 | PARADIGM BIOCAPITAL ADVISORS LP | 2.26M +395.6K (+21.2%) | 28.32M +6.7M (+31.0%) | 9.62% +1.683 pp | 0.72% +0.108 pp | USD11.74 +6.6% | 2 qtrs — |
| 11 | BLACKROCK, INC. | 2.08M +36.3K (+1.8%) | 26.10M +2.4M (+10.0%) | 8.87% +0.154 pp | 0.00% +0.000 pp | USD11.60 +7.9% | 2 qtrs — |
| 12 | NOVO HOLDINGS A/S | 1.96M +— (+0.0%) | 24.56M +1.8M (+8.1%) | 8.34% +0.000 pp | 1.91% +0.443 pp | USD11.58 +8.1% | 2 qtrs — |
| 13 | LAURION CAPITAL MANAGEMENT LP | 1.46M +419.1K (+40.1%) | 18.34M +6.2M (+51.4%) | 6.23% +1.783 pp | 0.68% +0.475 pp | USD11.85 +5.7% | 2 qtrs — |
| 14 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.40M -87.6K (-5.9%) | 17.53M +301.3K (+1.7%) | 5.96% -0.373 pp | 0.03% -0.001 pp | USD11.58 +8.1% | 2 qtrs — |
| 15 | EVENTIDE ASSET MANAGEMENT, LLC | 1.08M +— (+0.0%) | 13.39M +974.1K (+7.8%) | 4.60% +0.000 pp | 0.21% +0.005 pp | USD11.58 +8.1% | 2 qtrs — |
| 16 | OCTAGON CAPITAL ADVISORS LP | 1.04M +— (+0.0%) | 13.06M +980.5K (+8.1%) | 4.44% +0.000 pp | 1.59% -0.245 pp | USD11.58 +8.1% | 2 qtrs — |
| 17 | ARMISTICE CAPITAL, LLC | 1.00M +588.0K (+142.7%) | 12.52M +7.7M (+162.4%) | 4.25% +2.501 pp | 0.15% +0.078 pp | USD12.13 +3.2% | 2 qtrs — |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 803.1K -81.9K (-9.3%) | 10.06M -193.0K (-1.9%) | 3.42% -0.348 pp | 0.00% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 19 | VANGUARD GROUP INC | 791.1K +143.5K (+22.2%) | 9.90M +2.4M (+32.1%) | 3.37% +0.610 pp | 0.00% +0.000 pp | USD11.75 +6.6% | 2 qtrs — |
| 20 | AISLING CAPITAL MANAGEMENT LP | 564.6K +— (+0.0%) | 7.07M +530.7K (+8.1%) | 2.40% +0.000 pp | 1.48% +0.044 pp | USD11.58 +8.1% | 2 qtrs — |
| 21 | GEODE CAPITAL MANAGEMENT, LLC | 562.0K +20.4K (+3.8%) | 7.04M +764.9K (+12.2%) | 2.39% +0.087 pp | 0.00% +0.000 pp | USD11.61 +7.8% | 2 qtrs — |
| 22 | CASDIN CAPITAL, LLC | 282.3K +— (+0.0%) | 3.53M +265.4K (+8.1%) | 1.20% +0.000 pp | 0.22% -0.053 pp | USD11.58 +8.1% | 2 qtrs — |
| 23 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 279.0K -304.0 (-0.1%) | 3.49M +258.8K (+8.0%) | 1.19% -0.001 pp | 0.00% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 24 | MILLENNIUM MANAGEMENT LLC | 241.4K -128.1K (-34.7%) | 3.02M -1.0M (-25.5%) | 1.03% -0.545 pp | 0.00% -0.001 pp | USD11.58 +8.1% | 2 qtrs — |
| 25 | FMR LLC | 240.3K +78.2K (+48.3%) | 3.01M +1.1M (+60.3%) | 1.02% +0.333 pp | 0.00% +0.000 pp | USD11.89 +5.3% | 2 qtrs — |
| 26 | HIGHVISTA STRATEGIES LLC | 229.3K +229.3K (+100.0%) | 2.87M +2.9M (+100.0%) | 0.98% +0.975 pp | 0.74% +0.739 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 27 | ADAR1 CAPITAL MANAGEMENT, LLC | 226.2K -275.0K (-54.9%) | 2.83M -3.0M (-51.2%) | 0.96% -1.170 pp | 0.21% -0.337 pp | USD11.58 +8.1% | 2 qtrs — |
| 28 | IKARIAN CAPITAL, LLC | 220.2K -25.0K (-10.2%) | 2.76M -82.5K (-2.9%) | 0.94% -0.106 pp | 0.22% -0.072 pp | USD11.58 +8.1% | 2 qtrs — |
| 29 | STATE STREET CORP | 218.3K +41.6K (+23.5%) | 2.73M +686.7K (+33.6%) | 0.93% +0.177 pp | 0.00% +0.000 pp | USD11.76 +6.5% | 2 qtrs — |
| 30 | SIO CAPITAL MANAGEMENT, LLC | 130.6K +— (+0.0%) | 1.64M +122.8K (+8.1%) | 0.56% +0.000 pp | 0.26% -0.126 pp | USD11.58 +8.1% | 2 qtrs — |
| 31 | TD ASSET MANAGEMENT INC | 117.2K -12.9K (-9.9%) | 1.47M -39.4K (-2.6%) | 0.50% -0.055 pp | 0.00% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 32 | WOODLINE PARTNERS LP | 103.7K +— (+0.0%) | 1.30M +97.5K (+8.1%) | 0.44% +0.000 pp | 0.01% -0.001 pp | USD11.58 +8.1% | 2 qtrs — |
| 33 | MOORE CAPITAL MANAGEMENT, LP | 100.0K +— (+0.0%) | 1.25M +94.0K (+8.1%) | 0.43% +0.000 pp | 0.02% +0.002 pp | USD11.58 +8.1% | 2 qtrs — |
| 34 | GOLDMAN SACHS GROUP INC | 94.7K +94.7K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.40% +0.403 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 35 | UBS GROUP AG | 93.4K +41.1K (+78.8%) | 1.17M +564.2K (+93.3%) | 0.40% +0.175 pp | 0.00% +0.000 pp | USD11.99 +4.4% | 2 qtrs — |
| 36 | STEMPOINT CAPITAL LP | 86.5K -100.1K (-53.6%) | 1.08M -1.1M (-49.9%) | 0.37% -0.426 pp | 0.19% -0.247 pp | USD11.58 +8.1% | 2 qtrs — |
| 37 | RENAISSANCE TECHNOLOGIES LLC | 74.3K +74.3K (+100.0%) | 930.2K +930.2K (+100.0%) | 0.32% +0.316 pp | 0.00% +0.001 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 38 | BOOTHBAY FUND MANAGEMENT, LLC | 67.0K -29.5K (-30.6%) | 839.3K -278.8K (-24.9%) | 0.29% -0.126 pp | 0.01% -0.004 pp | USD11.58 +8.1% | 2 qtrs — |
| 39 | NORTHERN TRUST CORP | 58.0K -37.9K (-39.5%) | 726.6K -384.6K (-34.6%) | 0.25% -0.161 pp | 0.00% +0.000 pp | USD11.58 +8.1% | 2 qtrs — |
| 40 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 54.2K +54.2K (+100.0%) | 670.4K +670.4K (+100.0%) | 0.23% +0.231 pp | 0.00% +0.001 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 41 | QUBE RESEARCH & TECHNOLOGIES LTD | 36.0K +36.0K (+100.0%) | 450.1K +450.1K (+100.0%) | 0.15% +0.153 pp | 0.00% +0.001 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 42 | XTX TOPCO LTD | 28.6K +5.2K (+22.4%) | 358.5K +87.7K (+32.4%) | 0.12% +0.022 pp | 0.01% -0.005 pp | USD11.75 +6.6% | 2 qtrs — |
| 43 | BNP PARIBAS ARBITRAGE, SNC | 26.5K +26.5K (+100.0%) | 331.4K +331.4K (+100.0%) | 0.11% +0.113 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 44 | BIT CAPITAL GMBH | 25.0K +25.0K (+100.0%) | 313.0K +313.0K (+100.0%) | 0.11% +0.106 pp | 0.01% +0.012 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 45 | POINT72 ASSET MANAGEMENT, L.P. | 23.6K +23.6K (+100.0%) | 295.3K +295.3K (+100.0%) | 0.10% +0.100 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 46 | MORGAN STANLEY | 14.4K +13.5K (+1,566.9%) | 179.7K +169.7K (+1,702.3%) | 0.06% +0.057 pp | 0.00% +0.000 pp | USD12.46 +0.5% | 2 qtrs — |
| 47 | QUADRATURE CAPITAL LTD | 12.9K +12.9K (+100.0%) | 161.8K +161.8K (+100.0%) | 0.06% +0.055 pp | 0.00% +0.002 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 48 | SQUAREPOINT OPS LLC | 11.5K +11.5K (+100.0%) | 144.2K +144.2K (+100.0%) | 0.05% +0.049 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 49 | PERSISTENT ASSET PARTNERS LTD | 8.6K +8.6K (+100.0%) | 107.5K +107.5K (+100.0%) | 0.04% +0.037 pp | 0.05% +0.048 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 50 | CIBC PRIVATE WEALTH GROUP, LLC | 5.0K +5.0K (+100.0%) | 62.6K +62.6K (+100.0%) | 0.02% +0.021 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 51 | BANK OF AMERICA CORP /DE/ | 4.0K +2.7K (+200.2%) | 50.0K +34.6K (+224.6%) | 0.02% +0.011 pp | 0.00% +0.000 pp | USD12.21 +2.5% | 2 qtrs — |
| 52 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 700.00 +700.0 (+100.0%) | 8.8K +8.8K (+100.0%) | 0.00% +0.003 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 53 | WELLS FARGO & COMPANY/MN | 300.00 +300.0 (+100.0%) | 3.8K +3.8K (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD12.52 +0.0% | 1 qtrs NEW |
| 54 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | — -5.0K (-100.0%) | — -57.9K (-100.0%) | 0.00% -0.021 pp | 0.00% -0.005 pp | USD— | 2 qtrs SOLD |
| 55 | SILVERARC CAPITAL MANAGEMENT, LLC | — -457.4K (-100.0%) | — -5.3M (-100.0%) | 0.00% -1.946 pp | 0.00% -0.714 pp | USD— | 2 qtrs SOLD |
| 56 | FNY INVESTMENT ADVISERS, LLC | — -100.0 (-100.0%) | — -1.0K (-100.0%) | 0.00% 0.000 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 10 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.66% | 380.4K | 0.65% |
| 2 | Tema Oncology ETF CANC | 0.40% | 574.2K | 0.75% |
| 3 | State Street SPDR S&P Biotech ETF XBI | 0.06% | 6.78M | 0.35% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.06% | 21.8K | 0.45% |
| 5 | iShares Biotechnology ETF IBB | 0.03% | 2.59M | 0.44% |
| 6 | Pacer WealthShield ETF PWS | 0.01% | 3.1K | 0.60% |
| 7 | Direxion Daily S&P Biotech Bull 3X Shares LABU | 0.01% | 57.7K | 0.96% |
| 8 | Schwab U.S. Small-Cap ETF SCHA | 0.01% | 1.89M | 0.03% |
| 9 | Vanguard Extended Market ETF VXF | 0.01% | 4.76M | 0.05% |
| 10 | Schwab U.S. Broad Market ETF SCHB | 0.00% | 228.9K | 0.03% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.67
Neutral
Ratio by volume
3.00
Bullish
Buys
2
Sells
3
Shares acquired
1.86M
Shares disposed
2.6K
Cash buys
—
Cash sales
—
Net activity
+1,859,441
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-10 | Elmelech Idan | Officer | A-Award | A | Stock Option (Right to Buy) | 758,222 | 7.66 | 5.81M | 758,222 | D | ↗ |
| 2026-05-10 | Beltran Pedro | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,103,837 | 7.66 | 8.46M | 1,103,837 | D | ↗ |
| 2026-04-21 | Cobo Marc | Officer | — | — | Common Stock | 0 | 0.00 | — | 5,431 | D | ↗ |
| 2026-04-20 | Elmelech Idan | Officer | — | — | Stock Option (Right to Buy) | 129,678 | 4.17 | 540.8K | 0 | D | ↗ |
| 2026-04-01 | Mehra Uneek | Officer | F-InKind | D | Common Stock | 524 | 9.03 | 4.7K | 22,806 | D | ↗ |
| 2026-04-01 | Ben Yong | Officer | F-InKind | D | Common Stock | 1,047 | 9.03 | 9.5K | 45,623 | D | ↗ |
| 2026-04-01 | Beltran Pedro | Director / Officer | F-InKind | D | Common Stock | 1,047 | 9.03 | 9.5K | 45,623 | D | ↗ |
| 2026-03-24 | Lebowitz Peter F | Director | A-Award | A | Stock Option (Right to Buy) | 63,350 | 8.72 | 552.4K | 63,350 | D | ↗ |
| 2026-03-10 | Mehra Uneek | Officer | A-Award | A | Common Stock | 23,330 | 0.00 | — | 23,330 | D | ↗ |
| 2026-03-10 | Ben Yong | Officer | A-Award | A | Common Stock | 46,670 | 0.00 | — | 46,670 | D | ↗ |
| 2026-03-10 | Beltran Pedro | Officer | A-Award | A | Common Stock | 46,670 | 0.00 | — | 46,670 | D | ↗ |
| 2026-01-01 | Wallace Eli M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,114,400 | 12.52 | 13.95M | 1,114,400 | D | ↗ |
| 2025-12-10 | Wallace Eli M. | Director / Officer | D-Return | D | Stock Option (Right to Buy) | 1,114,400 | 12.44 | 13.86M | 500,000 | D | ↗ |
| 2025-10-10 | BridgeBio Pharma LLC | 10% Owner | J-Other | A | Common Stock | 784,720 | 0.00 | — | 14,589,846 | D | ↗ |
| 2025-10-02 | Wallace Eli M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 1,614,400 | 12.44 | 20.08M | 1,614,400 | D | ↗ |
| 2025-08-26 | Wallace Eli M. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 499,731 | 9.59 | 4.79M | 499,731 | D | ↗ |
| 2025-08-26 | Tipirneni Praveen P. | Director | A-Award | A | Stock Option (Right to Buy) | 52,269 | 9.59 | 501.3K | 52,269 | D | ↗ |
| 2025-08-26 | Mehra Uneek | Officer | A-Award | A | Stock Option (Right to Buy) | 633,570 | 9.59 | 6.08M | 633,570 | D | ↗ |
| 2025-08-26 | MCCORMICK FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 91,076 | 9.59 | 873.4K | 91,076 | D | ↗ |
| 2025-08-26 | Ben Yong | Officer | A-Award | A | Stock Option (Right to Buy) | 357,177 | 9.59 | 3.43M | 357,177 | D | ↗ |
| 2025-08-26 | Beltran Pedro | Officer | A-Award | A | Stock Option (Right to Buy) | 357,177 | 9.59 | 3.43M | 357,177 | D | ↗ |
| 2025-08-26 | Bauer Jake | Director | A-Award | A | Stock Option (Right to Buy) | 138,193 | 9.59 | 1.33M | 138,193 | D | ↗ |
| 2025-08-11 | Wallace Eli M. | Director / Officer | — | — | Stock Option (Right to Buy) | 37,172 | 7.88 | 292.9K | 0 | D | ↗ |
| 2025-08-11 | Tripp Caleb | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | Tipirneni Praveen P. | Director | — | — | Stock Option (Right to Buy) | 4,855 | 7.88 | 38.3K | 0 | D | ↗ |
| 2025-08-11 | Schmid John P. | Director | M-Exempt | A | Common Stock | 30,000 | 0.00 | — | 30,000 | D | ↗ |
| 2025-08-11 | Obradovic Nebojsa | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | Mehra Uneek | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | McKenna Mark C. | Director | M-Exempt | D | Class B ordinary shares | 30,000 | 0.00 | — | 0 | D | ↗ |
| 2025-08-11 | MCCORMICK FRANK | Director | — | — | Stock Option (Right to Buy) | 141,870 | 4.17 | 591.6K | 0 | D | ↗ |
| 2025-08-11 | Kumar Neil | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | Kelleher Raymond J. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | Holman Albert A III | Director | M-Exempt | D | Class B ordinary shares | 30,000 | 0.00 | — | 0 | D | ↗ |
| 2025-08-11 | DOIG MICHELLE | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-11 | Chen Bihua | Director / 10% Owner | M-Exempt | A | Common Stock | 4,172,126 | 0.00 | 417.21 | 4,681,126 | I | ↗ |
| 2025-08-11 | BridgeBio Pharma LLC | 10% Owner | — | — | Stock Option (Right to Buy) | 9,494 | 1.02 | 9.7K | 0 | D | ↗ |
| 2025-08-11 | Ben Yong | Officer | — | — | Stock Option (Right to Buy) | 26,551 | 7.88 | 209.2K | 0 | D | ↗ |
| 2025-08-11 | Beltran Pedro | Officer | — | — | Stock Option (Right to Buy) | 26,551 | 7.88 | 209.2K | 0 | D | ↗ |
| 2025-08-11 | Bauer Jake | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
80.11M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Yong Ben | Chief Medical & Development Officer | 771.0K | — |
| Pedro J. Beltran | Chief Executive Officer and Director | 767.7K | — |
| Eli Wallace | Chief Executive Officer and Director | 767.7K | male |
| Frank McCormick | Co-Founder, Non-Executive Director & Chair of the Advisory Board | 65.0K | — |
| Neil Kumar | Executive Chairman | 20.0K | — |
| Aaron Chan | Vice President of Legal | — | male |
| Marc Cobo | VP of Finance & Controller | — | male |
| Rui Xu | Senior Vice President of Drug Discovery | — | male |
| Uneek Mehra | Chief Financial Officer | — | male |
| Idan Elmelech | Chief Operating Officer | — | male |
| Angela Peters | Senior Vice President of People | — | female |
| Bin Wang | Senior Vice President of Drug Discovery | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BBOT
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
